These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24298871)

  • 1. [Polycystic kidney disease: from genetics to dialysis].
    Ortiz Arduan A
    An R Acad Nac Med (Madr); 2012; 129(2):687-96; discussion 697-9. PubMed ID: 24298871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
    Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
    Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality.
    Perrone RD; Ruthazer R; Terrin NC
    Am J Kidney Dis; 2001 Oct; 38(4):777-84. PubMed ID: 11576881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].
    Covic M; Covic M
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):11-20. PubMed ID: 18677899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Polycystic kidney diseases: molecular genetics and counselling].
    Lespinasse J; Fourcade J; Schir F
    Nephrol Ther; 2006 Jul; 2(3):120-6. PubMed ID: 16890136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies.
    Ibraghimov-Beskrovnaya O; Bukanov N
    Cell Mol Life Sci; 2008 Feb; 65(4):605-19. PubMed ID: 17975706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic Kidney/Liver Disease.
    Roediger R; Dieterich D; Chanumolu P; Deshpande P
    Clin Liver Dis; 2022 May; 26(2):229-243. PubMed ID: 35487607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
    Olalekan K; Fox A; Gilbert R
    Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycystic kidney disease: the cilium as a common pathway in cystogenesis.
    Lina F; Satlinb LM
    Curr Opin Pediatr; 2004 Apr; 16(2):171-6. PubMed ID: 15021197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic kidney disease: new understanding in the pathogenesis.
    Wilson PD
    Int J Biochem Cell Biol; 2004 Oct; 36(10):1868-73. PubMed ID: 15203099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cystic kidneys (autosomal dominant polycystic kidney disease)].
    Zeier M; Geberth S
    Ther Umsch; 1994 Dec; 51(12):801-6. PubMed ID: 7784992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent advances in molecular pathogenesis and polycystic kidney disease treatment].
    Covic M; Covic M
    Rev Med Chir Soc Med Nat Iasi; 2009; 113(1):13-22. PubMed ID: 21495291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update and review of adult polycystic kidney disease.
    Colbert GB; Elrggal ME; Gaur L; Lerma EV
    Dis Mon; 2020 May; 66(5):100887. PubMed ID: 31582186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Massive growth of kidneys in patients with autosomal dominant polycystic kidney disease treated with chronic hemodialysis.
    Milutinovic J
    Am J Kidney Dis; 1989 Nov; 14(5):365-8. PubMed ID: 2816929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in autosomal-dominant polycystic kidney disease.
    Rangan GK; Tchan MC; Tong A; Wong AT; Nankivell BJ
    Intern Med J; 2016 Aug; 46(8):883-92. PubMed ID: 27553994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trials and a View Toward the Future of ADPKD.
    Kim H; Hwang YH
    Adv Exp Med Biol; 2016; 933():105-121. PubMed ID: 27730438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic kidney disease: the complexity of planar cell polarity and signaling during tissue regeneration and cyst formation.
    Happé H; de Heer E; Peters DJ
    Biochim Biophys Acta; 2011 Oct; 1812(10):1249-55. PubMed ID: 21640821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease.
    Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T
    Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal replacement therapy in autosomal dominant polycystic kidney disease.
    Singh S; Hariharan S
    Nephron; 1991; 57(1):40-4. PubMed ID: 2046814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.